Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the maximally tolerated dose (MTD) and Phase 2 recommended dose of satraplatin when administered in combination with capecitabine in patients with advanced solid malignancies.


Clinical Trial Description

This is a single center, open-label, non-randomized, Phase I dose finding study of the investigational, oral cytotoxic drug, satraplatin in combination with capecitabine in patients with advanced solid tumors for whom curative therapy is not available. Please refer to the Eligibility Criteria below for key inclusion and exclusion criteria.

PURPOSE: The purpose of this trial is to determine a tolerable dose and schedule for the combination of satraplatin and docetaxel when given to patients with advanced solid tumors.

WHAT IS SATRAPLATIN: Satraplatin is an oral, investigational anticancer drug that is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00329329
Study type Interventional
Source Agennix
Contact
Status Terminated
Phase Phase 1
Start date May 2006
Completion date February 2009

See also
  Status Clinical Trial Phase
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT03236857 - A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies Phase 1
Completed NCT03005782 - Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers Phase 1
Not yet recruiting NCT05602103 - Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies
Completed NCT00316511 - Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma Phase 1
Withdrawn NCT05253105 - A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies Phase 1
Completed NCT02521389 - Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 Phase 1
Completed NCT01407380 - Study of PWT33597 Mesylate in Subjects With Advanced Malignancies Phase 1
Completed NCT01404728 - Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy N/A
Active, not recruiting NCT03678883 - 9-ING-41 in Patients With Advanced Cancers Phase 2
Not yet recruiting NCT05929495 - Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma Phase 2
Completed NCT02257476 - Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors Phase 1
Completed NCT00320827 - Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) Phase 1